Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
2.400
-0.030 (-1.23%)
Sep 26, 2025, 4:00 PM EDT - Market closed
Orchestra BioMed Holdings Stock Forecast
Stock Price Forecast
According to 3 professional analysts, the 12-month price target for Orchestra BioMed Holdings stock ranges from a low of $10 to a high of $20. The average analyst price target of $14 forecasts a 483.33% increase in the stock price over the next year.
Price Target: $14.00 (+483.33%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Orchestra BioMed Holdings stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +316.67% | Sep 4, 2025 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 20, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 | Strong Buy | Maintains | $20 | +733.33% | Aug 13, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 | Strong Buy | Maintains | $20 | +733.33% | Aug 7, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 | Strong Buy | Maintains | $20 | +733.33% | May 13, 2025 |
Financial Forecast
Revenue This Year
3.41M
from 2.64M
Increased by 29.26%
Revenue Next Year
3.77M
from 3.41M
Increased by 10.65%
EPS This Year
-1.87
from -1.66
EPS Next Year
-1.61
from -1.87
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.2M | 5.3M | |||
| Avg | 3.4M | 3.8M | |||
| Low | 2.9M | 2.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 59.2% | 54.0% | |||
| Avg | 29.3% | 10.6% | |||
| Low | 11.4% | -25.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.75 | -1.44 | |||
| Avg | -1.87 | -1.61 | |||
| Low | -2.02 | -1.72 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.